Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.64 |
| ▸ | CTSG | P08311 | 1/20 | 0.60 |
| ▸ | CMA1 | P23946 | 1/20 | 0.60 |
| ▸ | CTSL | P07711 | 4/20 | 0.58 |
| ▸ | CTSS | P25774 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7148922 | 1.00 | ACE (0.64) | ACECTSGCMA1CTSLCTSS | |
| SCHEMBL9581939 | 0.86 | ACE (0.66) | ACECTSLCTSSCTSKPTPN1 | |
| SCHEMBL9581928 | 0.86 | ACE (0.66) | ACECTSLCTSSCTSKPTPN1 | |
| SCHEMBL5664274 | 0.85 | CTSG (0.65) | ACECTSGCMA1L3MBTL1 | |
| SCHEMBL4291672 | 0.85 | CTSG (0.65) | ACECTSGCMA1L3MBTL1 | |
| SCHEMBL6942656 | 0.85 | CTSG (0.65) | ACECTSGCMA1L3MBTL1 | |
| SCHEMBL528464 | 0.83 | ACE (0.76) | ACECTSLCTSSCTSKPTPN1 | |
| SCHEMBL111236 | 0.83 | ACE (0.76) | ACECTSLCTSSCTSKPTPN1 | |
| SCHEMBL111235 | 0.83 | ACE (0.76) | ACECTSLCTSSCTSKPTPN1 | |
| SCHEMBL11125543 | 0.83 | ACE (0.75) | ACECTSLCTSSCTSKPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6888012-B2 | Reducing an alpha -haloketone compound by asymmetric hydrogen transfer in presence of a group 9 transition metal compound having a substituted or unsubstituted cyclopentadienyl group and an optically active diamine compound | AJINOMOTO CO., INC. (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20040082820-A1 | Hydrogen transfer reduction; useful as intermediate for production of pharmaceuticals/agricultural chemicals | AJINOMOTO CO., INC. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1346972-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE HALOHYDRIN COMPOUND | Ajinomoto Co., Inc. (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-5187290-A | Hypotensive agents, analgesics | E. R. SQUIBB & SONS, INC. (US) | 1993-02-16 | — | — | US | disclosed |
| US-4736066-A | Intermediate for substituted peptide compounds | E. R. SQUIBB & SONS, INC. (US) | 1988-04-05 | — | — | US | disclosed |
| EP-0154904-B1 | ACYLAMINO OXO OR HYDROXY SUBSTITUTED ALKYLAMINO THIAZINES AND THIAZEPINES | E.R. Squibb & Sons, Inc. (US) | 1987-10-28 | — | — | EP | disclosed |
| US-4692455-A | HYPOTENSIVE AGENTS, ANALGESICS | E. R. SQUIBB & SONS, INC. (US) | 1987-09-08 | — | — | US | disclosed |
| US-4636522-A | HYPOTENSIVE, ENZYME INHIBITORS, ANALGESICS | E. R. SQUIBB & SONS, INC. (US) | 1987-01-13 | — | — | US | disclosed |
| US-4604402-A | HYPOTENSIVE AGNETS | E. R. SQUIBB & SONS, INC. (US) | 1986-08-05 | — | — | US | disclosed |
| EP-0159156-A1 | Hydroxy substituted ureido amino and imino acids | E.R. Squibb & Sons, Inc. (US) | 1985-10-23 | — | — | EP | disclosed |
| EP-0154904-A1 | Acylamino oxo or hydroxy substituted alkylamino thiazines and thiazepines | E.R. Squibb & Sons, Inc. (US) | 1985-09-18 | — | — | EP | disclosed |
| US-4535176-A | HYPOTENSIVE AGENTS, ANALGESICS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1985-08-13 | — | — | US | disclosed |
| EP-0142335-A2 | Lactam containing compounds | E.R. Squibb & Sons, Inc. (US) | 1985-05-22 | — | — | EP | disclosed |
| US-4514391-A | HYPOTENSIVE AGENTS; ANALGESICS | E. R. SQUIBB & SONS, INC. (US) | 1985-04-30 | — | — | US | disclosed |
| US-4512988-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-04-23 | — | — | US | disclosed |
| EP-0132304-A2 | Hydroxy substituted peptide compounds | E.R. Squibb & Sons, Inc. (US) | 1985-01-30 | — | — | EP | disclosed |
| US-4474778-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1984-10-02 | — | — | US | disclosed |
| US-4470973-A | HYPOTENSIVE AGENTS, ANALGESICS | E. R. SQUIBB & SONS, INC. (US) | 1984-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082820-A1 | Hydrogen transfer reduction; useful as intermediate for production of pharmaceuticals/agricultural chemicals | DHPS, HDHD5, HYPK | ACE 1143/4885CTSG 2351/4885CMA1 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.